The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
The global preclinical antibacterial pipeline
Open accessAbstract
Antibacterial resistance is a great concern and requires global action. A critical question is whether enough new antibacterial drugs are being discovered and developed. A review of the clinical antibacterial drug pipeline was recently published, but comprehensive information about the global preclinical pipeline is unavailable. This Review focuses on discovery and preclinical development projects and has found, as of 1 May 2019, 407 antibacterial projects from 314 institutions. The focus is on Gram-negative pathogens, particularly bacteria on the WHO priority bacteria list. The preclinical pipeline is characterized by high levels of diversity and interesting scientific concepts, with 135 projects on direct-acting small molecules that represent new classes, new targets or new mechanisms of action. There is also a strong trend towards non-traditional approaches, including diverse antivirulence approaches, microbiome-modifying strategies, and engineered phages and probiotics. The high number of pathogen-specific and adjunctive approaches is unprecedented in antibiotic history. Translational hurdles are not adequately addressed yet, especially development pathways to show clinical impact of non-traditional approaches. The innovative potential of the preclinical pipeline compared with the clinical pipeline is encouraging but fragile. Much more work, focus and funding are needed for the novel approaches to result in effective antibacterial therapies to sustainably combat antibacterial resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142
Self-citationEuropean consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
Natural Products as Platforms To Overcome Antibiotic Resistance
Rossiter, S. E., Fletcher, M. H., & Wuest, W. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00283 · Cited by 622
Fleitas Martínez, O., Cardoso, M. H., Ribeiro, S. M., & Franco, O. L. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00074 · Cited by 304
Fighting bacterial persistence: Current and emerging anti-persister strategies and therapeutics
Defraine, V., Fauvart, M., & Michiels, J. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.03.002 · Cited by 222
Cited by
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Shaping the Future of Probiotics and Prebiotics
Cunningham, M., Azcarate-Peril, M. A., Barnard, A., Benoit, V., Grimaldi, R., Guyonnet, D., Holscher, H. D., Hunter, K., Manurung, S., Obis, D., et al. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.01.003 · Cited by 637
Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics
Murugaiyan, J., Kumar, P. A., Rao, G. S., Iskandar, K., Hawser, S., Hays, J. P., Mohsen, Y., Adukkadukkam, S., Awuah, W. A., Jose, R. A. M., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11020200 · Cited by 567
A New Era of Antibiotics: The Clinical Potential of Antimicrobial Peptides
Browne, K., Chakraborty, S., Chen, R., Willcox, M. D., Black, D. S., Walsh, W. R., & Kumar, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197047 · Cited by 482
Infection microenvironment-related antibacterial nanotherapeutic strategies
Wang, Z., Liu, X., Duan, Y., & Huang, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121249 · Cited by 268
Metadata
- Authors
- Theuretzbacher, U., Outterson, K., Engel, A., & Karlén, A.
- Venue
- Nature Reviews Microbiology
- Published
- 2019-11-19
- Volume
- 18
- Issue
- 5
- Pages
- 275-285
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- OpenAlex
- W2991330881
- Cited by
- 738
- References
- 5
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The global preclinical antibacterial pipeline. https://app.cochat.ai/papers/10.1038/s41579-019-0288-0
- The paper
- Theuretzbacher, U., Outterson, K., Engel, A., & Karlén, A. (2020). The global preclinical antibacterial pipeline. Nature Reviews Microbiology. https://doi.org/10.1038/s41579-019-0288-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.